Operation Warp Speed For Rare Diseases? US FDA Is Considering Pilot Programs
Executive Summary
CBER director Peter Marks says the FDA may evaluate giving gene therapy products the ‘degree of responsiveness’ that COVID-19 vaccines received. In a discussion of the pandemic's effects on staff retention, CDER director Patrizia Cavazzoni says attrition rates are back to historical levels.
You may also be interested in...
Product Differences Necessitate Some US FDA Inconsistency In Rare Diseases, Center Directors Say
Development standards for a one-time gene therapy should be different from a drug taken regularly, CBER Director Peter Marks says.
US FDA’s Cell/Gene Therapy Office Looks To Improve Clarity Of Advice Through Written Responses
Standardizing the process for providing clarifications following sponsor meetings, particularly with regard to the written response-only format, is one of several solutions being piloted by the Office of Tissues and Advanced Therapies as part of its ‘growth program,’ which aims to expedite advances in cell/gene therapies while also improving staff satisfaction.
US FDA May Rethink White Oak Campus As Agency Plots ‘New Normal’ For Work
A pilot project on the future of work at the FDA could lead to reduced office space requirements and improve recruitment and retention, officials say.